ABL1 and myeloproliferative neoplasm: After identifying MPL and CALR mutations, the three driver genes are now available for a revised 2022 WHO classification, which highlights the importance of genetic testing in BCR::ABL1-negative MPN, and have become essential for the definitive diagnosis of BCR::ABL1-negative MPNs [1,2].